BLOG / 🇮🇳 India / regulatory compliance · · daily

India BSE NSE Trading Suspension Orders — November 05, 2026

India Trading Suspensions & Delistings

By Gunpowder Editorial ·

7 high priority 7 total filings analysed

Executive Summary

The stream 'India Trading Suspensions & Delistings' is scoped to trading halts, suspensions, and delisting announcements with event type Regulatory Action.

Of the seven filings, the strongest in-scope regulatory developments are the SEBI Final Order against Purple Agrotech (four-year market restraint and ₹50 lakh penalty, stayed by SAT subject to deposit), the NCLAT annulment of CIRP against Shilpa Medicare's subsidiary FTF Pharma, the Fortis Healthcare SFIO/SEBI investigations concerning erstwhile promoters, and the Urja Global SEBI penalty of ₹90 lakh under appeal. Praxis Home Retail's material going-concern uncertainty, negative net worth of ₹(10,085.14) lakh, and pending NCLT insolvency petition are the most acute distress signals. Period-over-period data shows widespread top-line weakness among the smaller names: Purple Agrotech's H1 FY27 total income fell to ₹171.30 lakh from ₹2,101.10 lakh for FY26, and Urja Global's EV, battery, and renewable segment revenues fell 43%, 53%, and 14% YoY respectively. Fortis is the outlier with growing revenue (Q2 revenue from operations up 13.9% YoY) but flat six-month PAT and a 17% YoY decline in pre-exceptional PBT. Governance overhangs, not operating results, are driving the risk profile across the group.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Corporate governance · Insolvency

Tracking the trend? Catch up on the prior India BSE NSE Trading Suspension Orders digest from November 04, 2026.

Investment Signals (10)

  • ▲

    NCLAT set aside the NCLT Ahmedabad order admitting CIRP against wholly owned subsidiary FTF Pharma (order dated 4 Nov 2026); company states no quantifiable impact on the listed entity

  • Q2 FY27 revenue from operations ₹519 Cr, up 13.9% YoY (6.1% QoQ), total income up 11.5% YoY; six-month EBITDA rose to ₹33,735 lacs from ₹32,042 lacs

  • Current ratio improved to 0.47 from 0.33 at March 31, 2026, and finance costs fell to ₹9,157 lacs from ₹10,254 lacs for six months

  • Q2 profit before tax excluding exceptional items declined 17.0% YoY on higher employee and professional fees; six-month PAT essentially flat at ₹17,769 lacs vs ₹17,697 lacs

  • Trade receivables rose to ₹30,794 L from ₹23,980 L since March 31, 2026 (up ~28%), while debtors turnover fell to 3.68 from 4.25, signalling slower cash conversion

  • Purple Agrotech (MIXED)
    ▲

    Cash fell to ₹65.18 lakh from ₹589.73 lakh and borrowings were cut to ₹22.00 lakh from ₹896.25 lakh; finance costs down ~54.5% YoY to ₹8.95 lakh, a deleveraging signal amid shrinking operations

  • Purple Agrotech (BEARISH)
    ▲

    Half-year revenue from operations nil vs ₹141.49 lakh a year earlier, and total assets down to ₹1,220.22 lakh from ₹2,109.30 lakh since March 31

  • ▲

    Consolidated revenue fell ~43% YoY in EV, ~53% in batteries and ~14% in renewables, with no segment growing; CEO transition (Sunil Kumar Singh effective 5 Nov 2026) and CFO appointment (effective 19 Dec 2026) pending

  • Q2 FY27 total income ₹2,619.48 lakh, up ~16.7% YoY, but loss before tax of ₹(1,280.15) lakh versus a prior-year profit of ₹8,104.26 lakh driven by a one-time exceptional gain

  • Rights issue of up to ₹5,500 lakh is the principal capital-raising route against net current liabilities of ₹8,336.52 lakh; execution would be a key positive catalyst

Risk Flags (8)

  • Auditor (Singhi & Co.) issued Material Uncertainty Related to Going Concern; negative net worth of ₹(10,085.14) lakh and half-year cash loss of ₹2,155.64 lakh

  • Operational creditor Koncepts Interior (claim ~₹107 lakh) petition pending before NCLT Mumbai, adding to several insolvency and tribunal proceedings

  • ▼

    SEBI penalty of ₹90 lakh under appeal alongside multiple GST and income-tax demands; auditor emphasis-of-matter on undocumented mining investments (CWIP ₹46.35 Cr) and a ₹36.46 Cr debtor set-off

  • ▼

    ₹30.76 Cr receivables of which ₹20.34 Cr aged over 180 days; ₹28.81 Cr interest-free loan from promoter company Nandanvan Commercial Pvt Ltd outstanding since inception

  • ▼

    Supreme Court-directed forensic audit (via Delhi High Court), SEBI show-cause and penalty proceedings, an SFIO investigation and EOW complaints relating to erstwhile promoters remain open; management expects no material further impact but outcomes are unquantified

  • Purple Agrotech/SEBI Order [MEDIUM RISK]
    ▼

    SEBI Final Order dated June 30, 2026 imposes four-year market access restraint and ₹50 lakh penalty; SAT stay (11 Sep 2026) is conditional on deposit, and penalty was paid 7 Oct 2026

  • Purple Agrotech/Earnings Quality [MEDIUM RISK]
    ▼

    Q2 FY27 PAT of ₹11.26 lakh vs ₹12.35 lakh (down ~8.8%) despite nil revenue from operations; reported profit appears driven by non-operating items against a shrinking balance sheet

  • Underlying dispute with operational creditor Immacule Lifesciences over a Technology Transfer Agreement, disputed milestone payments and a disputed third-party testing invoice remain unresolved even after annulment; appeal filed by suspended FTF Pharma director Abhay Sapre

Opportunities (6)

  • NCLAT removal of CIRP against FTF Pharma (order 4 Nov 2026, received 5 Nov 2026) removes a subsidiary insolvency overhang; company reports no quantifiable impact, supporting a re-rating thesis if the commercial dispute is settled

  • Revenue from operations up 13.9% YoY and six-month EBITDA up ~5.3%; with current ratio improving to 0.47, the operating business is strengthening beneath the governance overhang

  • ₹706 L reversal of subsidiary impairment in Q2 FY27 (vs ₹2,183 L prior year) signals recovering carrying values on investments; a further write-back trend would lift reported earnings

  • Proposed rights issue of up to ₹5,500 lakh could cure a ₹8,336.52 lakh net current liability position and the negative net worth if fully subscribed; recapitalisation is the critical catalyst

  • Purple Agrotech/Balance Sheet Cleanup (OPPORTUNITY)
    ◆

    Borrowings reduced by ~97% (₹896.25 lakh to ₹22.00 lakh) and finance costs down 54.5% YoY; a clean balance sheet with minimal debt leaves a small but debt-free shell available for strategic repositioning

  • New CEO effective 5 Nov 2026 and CFO effective 19 Dec 2026 offer a window to address the receivables, undocumented investments and related-party loan issues flagged by the auditor

Sector Themes (6)

  • Governance Overhang Across Listed Names
    ◆

    Four of seven filings carry active SEBI, SFIO, NCLT or auditor qualifications (Urja Global, Purple Agrotech, Fortis Healthcare, Praxis Home Retail), with penalties and proceedings ranging from ₹50 lakh to ongoing forensic audits; regulatory exposure, not operations, is the dominant risk theme

  • Top-Line Contraction in Micro-Caps
    ◆

    Purple Agrotech (H1 total income ₹171.30 lakh vs ₹2,101.10 lakh for FY26) and Urja Global (segment revenues down 14–53% YoY) show revenue erosion, while Praxis shows growth in total income but deepening losses; the divergence between revenue and profitability is the key analytical lens

  • Balance Sheet Stress Concentrated in Distressed Names
    ◆

    Praxis's negative net worth and ₹8,336.52 lakh net current liabilities contrast with Fortis's improving current ratio (0.33 to 0.47) and Purple's deleveraging, indicating that solvency risk is idiosyncratic rather than sector-wide

  • Insolvency Mechanism Actively Contested
    ◆

    Shilpa's CIRP annulment on appeal and Praxis's pending NCLT petition show tribunals being used both to admit and to reverse insolvency proceedings; appellate outcomes can rapidly change a subsidiary's status

  • Receivables Quality Deteriorating
    ◆

    Fortis trade receivables up ~28% since March 31 with slower debtor turnover, and Urja's ₹20.34 Cr of ₹30.76 Cr receivables aged over 180 days, point to collection stress across the group

  • Management Transitions Under Regulatory Scrutiny
    ◆

    Urja's CEO and CFO changes, and Fortis's and Purple's references to erstwhile or suspended promoters, show ownership and leadership changes are a recurring feature of distressed governance cases

Watch List (7)

  • Track rights issue size (up to ₹5,500 lakh), subscription outcome and Koncepts Interior petition hearing; going-concern status depends on both

  • Monitor Delhi High Court forensic audit directions, SEBI penalty decisions and SFIO findings; next results period will show whether exceptional items and litigation provisions move

  • New CEO effective 5 Nov 2026 and CFO effective 19 Dec 2026; watch for SEBI penalty appeal outcome (₹90 lakh) and resolution of CWIP and promoter loan issues

  • Watch for further appeal by Immacule Lifesciences or related creditors after NCLAT order of 4 Nov 2026, and any settlement of the Technology Transfer Agreement milestone dispute

  • Purple Agrotech/SAT Final Hearing
    👁

    SAT stay on SEBI four-year market restraint is conditional on deposit (penalty paid 7 Oct 2026); final SAT outcome and next revenue-generating activity will determine whether the company remains a viable listed entity

  • Watch whether Q2 PBT decline (-17.0% YoY pre-exceptional) reverses as employee and professional fee growth moderates, and whether receivables stabilise after the ~28% increase since March

  • Track ₹20.34 Cr of receivables aged over 180 days and the ₹36.46 Cr debtor set-off for provisioning or write-off in subsequent filings

Filing Analyses (7)
Urja Global Limited Corporate Governance negative materiality 8/10

05-11-2026

Urja Global Limited's Board approved unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, and appointed Mr. Sunil Kumar Singh as CEO (effective November 5, 2026) and Mr. Vipul Jain as CFO (effective December 19, 2026). The statutory auditors issued a qualified-style limited review with extensive emphasis-of-matter paragraphs covering undocumented mining investments and loans, a ₹36.46 Cr debtor set-off, ₹30.76 Cr of receivables (₹20.34 Cr aged over 180 days), a SEBI penalty of ₹90 lakh under appeal, and multiple GST and income-tax demands. Reported results are weak relative to the prior year, with mixed segment performance.

  • · Consolidated revenue from Electric Vehicle segment fell about 43% YoY, Batteries about 53% and Renewable Energy about 14%, with no segment showing growth.
  • · Auditor flagged no documentary evidence for mines investments and loans/advances (CWIP of ₹46.35 Cr), with recoverability not determinable after a 2021 GST raid removed records.
  • · Outstanding ₹28.81 Cr loan from promoter company Nandanvan Commercial Pvt Ltd carries no interest since inception.
  • · Income-tax e-proceedings notices have lapsed without replies; outstanding tax liability of ₹6.24 Cr excluding interest.
  • · Multiple GST demands include a ₹44.15 Cr order (FY2018-19 to 2020-21) and ₹14.97 Cr ITC recovery, with appeals or writs pending.
  • · CFO appointment takes effect only on December 19, 2026, leaving a gap after the CEO appointment.
Shilpa Medicare Limited Insolvency positive materiality 4/10

05-11-2026

Shilpa Medicare Limited disclosed that the National Company Law Appellate Tribunal (NCLAT), New Delhi, by order dated 4 November 2026, set aside the NCLT Ahmedabad Bench order dated 9 September 2026 that had admitted Corporate Insolvency Resolution Process (CIRP) proceedings against FTF Pharma Private Limited, its wholly owned subsidiary, and consequently the CIRP stands annulled. The company states there is no quantifiable impact on the listed entity from the earlier order being annulled. The appeal was filed by Mr. Abhay Sapre, a suspended director of FTF Pharma, against the operational creditor Immacule Lifesciences Private Limited.

  • · NCLAT order dated 4 November 2026 in Comp. App. (AT) (Ins) No. 1781 of 2026 set aside the NCLT Ahmedabad order dated 9 September 2026 (C.P. (IB) No. 346 (Ahm) of 2025)
  • · Company received the order on 5 November 2026 and disclosed it under Regulation 30 of SEBI Listing Regulations
  • · Company states the appeal's underlying dispute concerns a Technology Transfer Agreement with an operational creditor, with disputed milestone payments and a disputed invoice for third-party testing
  • · Annulment of CIRP is characterised by the company as having no impact on the listed entity
Purple Entertainment Limited Corporate Governance mixed materiality 6/10

05-11-2026

Purple Agrotech Industries Limited (formerly Purple Entertainment Limited) reported unaudited results for the quarter and half year ended September 30, 2026, with Q2 profit after tax of ₹11.26 lakh versus ₹12.35 lakh in the prior-year quarter (not a like-for-like comparison, as Q2 FY26 revenue was nil) and H1 FY27 PAT of ₹14.28 lakh versus ₹22.25 lakh in the corresponding prior-year period, a decline. Total income for H1 FY27 fell to ₹171.30 lakh from ₹2,101.10 lakh for FY26, reflecting a sharp drop in trading revenue, although revenue from operations was nil in the current quarter and half year. The company also disclosed a SEBI Final Order dated June 30, 2026 (four-year market restraint and a ₹50 lakh penalty), which SAT stayed on September 11, 2026 subject to deposit; the penalty was paid on October 7, 2026.

  • · Q2 FY27 PAT of ₹11.26 lakh is versus ₹12.35 lakh in Q2 FY26, a decline of about 8.8%, which the summary does not state.
  • · Finance costs for H1 FY27 were ₹8.95 lakh, down from ₹19.67 lakh in H1 FY26, a decline of about 54.5%.
  • · Cash and cash equivalents fell to ₹65.18 lakh at Sep 30, 2026 from ₹589.73 lakh at March 31, 2026, and borrowings fell from ₹896.25 lakh to ₹22.00 lakh.
  • · Trade receivables declined to ₹508.79 lakh from ₹606.59 lakh, and inventories of ₹47.79 lakh appeared against nil at March 31, 2026.
  • · Net worth (shareholders' funds) rose to ₹1,042.12 lakh from ₹1,027.85 lakh, reflecting the H1 profit.
Purple Entertainment Limited Market Update mixed materiality 5/10

05-11-2026

Purple Agrotech Industries Limited (formerly Purple Entertainment Limited) reported unaudited results for the quarter and half year ended September 30, 2026, with Q2 FY27 total income of ₹25.16 lakh versus ₹146.14 lakh in the immediately preceding quarter, and profit after tax of ₹11.26 lakh versus ₹3.02 lakh; however, revenue from operations was nil in the current quarter compared with ₹141.49 lakh in the prior quarter, and the year-ago quarter also showed nil revenue, with profit after tax of ₹12.35 lakh. The company also disclosed a SEBI Final Order dated June 30, 2026 imposing a four-year market access restraint and a ₹50 lakh penalty, which SAT stayed on September 11, 2026 subject to deposit; the penalty was paid on October 7, 2026.

  • · Total income for the half year ended September 30, 2026 was ₹171.30 lakh versus ₹2,101.10 lakh for the year ended March 31, 2026, while half-year profit after tax was ₹14.28 lakh versus ₹16.45 lakh for FY26 (audited).
  • · Half-year revenue from operations was nil versus ₹141.49 lakh in the corresponding prior half year.
  • · Total assets declined to ₹1,220.22 lakh from ₹2,109.30 lakh at March 31, 2026, and cash and cash equivalents fell to ₹65.18 lakh from ₹589.73 lakh, with borrowings reduced to ₹22.00 lakh (non-current) from ₹896.25 lakh combined.
  • · Shareholders' funds rose to ₹1,042.12 lakh from ₹1,027.85 lakh, with other equity at ₹177.52 lakh versus ₹163.25 lakh.
  • · Inventories of ₹47.79 lakh appeared on the balance sheet for the first time, reflecting a stock-in-trade change in the quarter.
  • · The SEBI order also restrained the company from accessing securities markets and dealing in securities for four years; SAT's stay was conditional on full penalty deposit, which was completed on October 7, 2026.
  • · Statement figures are in ₹ lakh (₹10 lakh = ₹0.1 crore); equity share capital is unchanged at ₹864.60 lakh (face value ₹10 per share).
Fortis Healthcare Limited Corporate Governance mixed materiality 8/10

05-11-2026

Fortis Healthcare reported unaudited standalone results for the quarter and six months ended September 30, 2026, with Q2 FY27 total income of ₹61,091 lacs (up from ₹54,823 lacs in the prior-year quarter) and revenue from operations of ₹51,941 lacs (up 14% YoY from ₹45,581 lacs), though revenue was up only 6% QoQ from ₹48,945 lacs. Net profit from continuing operations rose to ₹12,991 lacs in the quarter versus ₹12,509 lacs a year earlier, but six-month PAT was essentially flat at ₹17,769 lacs against ₹17,697 lacs, and EBITDA for the six months grew to ₹33,735 lacs from ₹32,042 lacs. The filing also carries ongoing governance and regulatory overhangs: the Supreme Court-directed forensic audit by the Delhi High Court, SEBI show-cause and penalty proceedings, an SFIO investigation, and EOW complaints relating to erstwhile promoters.

  • · Six-month total income rose to ₹111,928 lacs from ₹102,127 lacs, while six-month other income fell to ₹11,042 lacs from ₹13,243 lacs.
  • · Total expenses for the six months rose to ₹93,442 lacs from ₹86,203 lacs, and finance costs declined to ₹9,157 lacs from ₹10,254 lacs.
  • · Basic and diluted EPS for the six months was ₹2.35, versus ₹2.34 in the prior-year period.
  • · Trade receivables increased to ₹30,794 lacs from ₹23,980 lacs as of March 31, 2026, and allowance for doubtful receivables rose to 3.78% of receivables for the six months from 2.11% a year earlier.
  • · Debtors turnover fell to 3.68 for the six months from 4.25, and the current ratio improved to 0.47 from 0.41.
  • · Net worth stood at ₹940,223 lacs, and the company sought to recover ₹40,300 lacs plus interest from erstwhile promoters under SEBI directions.
  • · The Delhi High Court ordered a forensic audit on August 31, 2026, which the Supreme Court allowed to proceed on September 25, 2026.
  • · Management believes no adjustment is required to the results for the Fortis brand trademark and SRL brand matters, which remain subject to legal proceedings.
  • · Under Ind AS 19, a one-time ₹1,035 lacs impact from the New Labour Codes was recognised as an exceptional item in FY26.
Fortis Healthcare Limited Corporate Governance mixed materiality 7/10

05-11-2026

Fortis Healthcare reported unaudited standalone results for Q2 FY27 (quarter ended September 30, 2026) with total income of ₹611 Cr (vs ₹548 Cr in Q2 FY26, up 11.5%) and net profit of ₹130 Cr (vs ₹125 Cr, up 3.9%), though net profit fell sharply from ₹48 Cr in the preceding quarter. Revenue from operations rose 13.9% YoY to ₹519 Cr, but sequential growth was 6.1%, and Q2 profit before tax excluding exceptional items declined 17.0% YoY on higher employee and professional fees. The filing also continues to disclose the ongoing SFIO/SEBI investigations and related legal proceedings concerning erstwhile promoters, with management stating no material further impact is expected.

  • · Exceptional gain of ₹706 L in Q2 FY27 from reversal of impairment in subsidiary investments, versus ₹2,183 L in Q2 FY26
  • · Trade receivables rose to ₹30,794 L from ₹23,980 L at March 31, 2026, while allowance for doubtful receivables reached 3.78% of receivables for six months
  • · Current ratio improved to 0.47 from 0.33 at March 31, 2026, while debtors turnover declined to 3.68 for six months from 4.25 a year earlier
  • · Net cash from operating activities rose to ₹16,907 L for six months from ₹2,489 L a year earlier, but net cash used in financing was ₹24,040 L
  • · Ongoing SEBI penalty appeals (₹100 L and ₹50 L on Company and FHsL; ₹100 L on EHIRCL) remain pending before SAT Mumbai
  • · Brand License related claim by Headway Brands ex-director seeks ~₹362 Cr, pending before Delhi High Court
Praxis Home Retail Limited Market Update negative materiality 8/10

05-11-2026

Praxis Home Retail Limited's Board approved unaudited results for the quarter and half year ended September 30, 2026, showing a half-year cash loss of ₹2155.64 lakh and a negative net worth of ₹(10,085.14) lakh, with a Material Uncertainty Related to Going Concern flagged by the auditor, Singhi & Co. Total income for Q2 FY27 was ₹2,619.48 lakh versus ₹2,245.51 lakh in Q2 FY26 (up ~16.7%), but loss before tax widened to ₹(1,280.15) lakh from a prior-year profit of ₹8,104.26 lakh, which was driven by a one-time exceptional gain. The company is pursuing a rights issue of up to ₹5,500 lakh and faces several insolvency and tribunal proceedings.

  • · Net current liabilities of ₹8,336.52 lakh as of September 30, 2026
  • · Auditor issued a Material Uncertainty Related to Going Concern with an unmodified conclusion
  • · Insolvency petition by operational creditor Koncepts Interior (claim ~₹107 lakh) pending before NCLT Mumbai
  • · GST Appellate Tribunal ordered deposit of ₹367.88 lakh profiteered amount with interest at 18%; company evaluating appeal
  • · NCLT order against company re Ojas Tradelease lease; ₹1,955 lakh claimed, under appeal before NCLAT
  • · NCRPs of ₹630 lakh issued to Future Enterprises Ltd remain unredeemed since December 8, 2022
  • · Promoter reclassification request to public category returned by NSE; company resubmitting documents
  • · Stock options of 22,05,000 granted to eligible employees on August 7, 2026

Get daily alerts with 10 investment signals, 8 risk alerts, 6 opportunities and full AI analysis of all 7 filings

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: India BSE NSE Trading Suspension Orders

🇮🇳 More from India

View all →